Expert: Agonist monoclonal antibody targeting the leptin receptor (LEPR). Mimics leptin signaling without requiring functional adipose tissue. Reduces hyperphagia, insulin resistance, hypertriglyceridemia, and hepatic steatosis in lipodystrophy.

Everyday: Activates the leptin receptor, mimicking the natural hormone leptin that controls appetite and metabolism. In patients with lipodystrophy who have no fat tissue (and therefore no leptin), this drug replaces the missing signal that tells the body to regulate blood sugar and fat.

Targets: ["LEPR"]

LEPR agonist antibody for generalized lipodystrophy. Mimics leptin signaling to restore metabolic homeostasis. Addresses severe insulin resistance, diabetes, and hypertriglyceridemia in GL patients. Potential to replace metreleptin (Myalept). Ph3 ongoing.